Glenview Trust co Has $13.36 Million Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Glenview Trust Co. reduced its stake in Thermo Fisher Scientific by 6.7% during the first quarter, leaving them with 26,853 shares valued at approximately $13.36 million.
• Thermo Fisher reported Q2 earnings per share of $5.36, surpassing analysts' estimates, with a net margin of 15.24% and a year-over-year revenue increase of 2.9%.
• The company announced a quarterly dividend of $0.43 per share, with the dividend yield currently at 0.4% and a payout ratio of 9.95%.

Glenview Trust co reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,853 shares of the medical research company's stock after selling 1,923 shares during the quarter. Glenview Trust co's holdings in Thermo Fisher Scientific were worth $13,362,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. Bernard Wealth Management Corp. bought a new stake in Thermo Fisher Scientific during the fourth quarter worth $25,000. Ameriflex Group Inc. bought a new stake in Thermo Fisher Scientific during the fourth quarter worth $30,000. Keystone Global Partners LLC bought a new stake in Thermo Fisher Scientific during the first quarter worth $31,000. IMA Advisory Services Inc. bought a new stake in Thermo Fisher Scientific during the first quarter worth $35,000. Finally, Smallwood Wealth Investment Management LLC bought a new stake in Thermo Fisher Scientific during the first quarter worth $37,000. 89.23% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO Marc N. Casper sold 400 shares of the firm's stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. This trade represents a 0.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,066 shares of company stock worth $14,182,963. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock traded down $11.93 on Friday, hitting $479.48. The company's stock had a trading volume of 1,543,232 shares, compared to its average volume of 1,555,589. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The stock's 50 day moving average is $466.86 and its 200-day moving average is $451.65. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $623.77. The company has a market capitalization of $181.06 billion, a PE ratio of 27.73, a PEG ratio of 2.62 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the prior year, the company posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Wall Street Analysts Forecast Growth

TMO has been the topic of several research analyst reports. Evercore ISI dropped their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Raymond James Financial reissued an "outperform" rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Barclays raised shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $490.00 to $550.00 in a research report on Thursday. Finally, Wall Street Zen lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, September 7th. Seventeen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $592.24.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.